Logo image of TNG.PA

TRANSGENE SA (TNG.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:TNG - FR0005175080 - Common Stock

1.02 EUR
-0.06 (-5.56%)
Last: 11/28/2025, 5:26:44 PM
Fundamental Rating

1

Taking everything into account, TNG scores 1 out of 10 in our fundamental rating. TNG was compared to 78 industry peers in the Biotechnology industry. TNG has a bad profitability rating. Also its financial health evaluation is rather negative. TNG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TNG has reported negative net income.
TNG had a negative operating cash flow in the past year.
TNG had negative earnings in each of the past 5 years.
TNG had a negative operating cash flow in each of the past 5 years.
TNG.PA Yearly Net Income VS EBIT VS OCF VS FCFTNG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

TNG has a Return On Assets of -82.88%. This is in the lower half of the industry: TNG underperforms 66.67% of its industry peers.
Industry RankSector Rank
ROA -82.88%
ROE N/A
ROIC N/A
ROA(3y)-59.77%
ROA(5y)-43.73%
ROE(3y)-151.05%
ROE(5y)-103.3%
ROIC(3y)N/A
ROIC(5y)N/A
TNG.PA Yearly ROA, ROE, ROICTNG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

TNG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNG.PA Yearly Profit, Operating, Gross MarginsTNG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

TNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNG has more shares outstanding
The number of shares outstanding for TNG has been increased compared to 5 years ago.
Compared to 1 year ago, TNG has an improved debt to assets ratio.
TNG.PA Yearly Shares OutstandingTNG.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TNG.PA Yearly Total Debt VS Total AssetsTNG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.32, we must say that TNG is in the distress zone and has some risk of bankruptcy.
TNG has a Altman-Z score of -3.32. This is in the lower half of the industry: TNG underperforms 62.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.32
ROIC/WACCN/A
WACC7.7%
TNG.PA Yearly LT Debt VS Equity VS FCFTNG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

TNG has a Current Ratio of 0.54. This is a bad value and indicates that TNG is not financially healthy enough and could expect problems in meeting its short term obligations.
TNG has a worse Current ratio (0.54) than 79.49% of its industry peers.
TNG has a Quick Ratio of 0.54. This is a bad value and indicates that TNG is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of TNG (0.54) is worse than 78.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
TNG.PA Yearly Current Assets VS Current LiabilitesTNG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

TNG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.17%.
Looking at the last year, TNG shows a very negative growth in Revenue. The Revenue has decreased by -20.34% in the last year.
Measured over the past years, TNG shows a very negative growth in Revenue. The Revenue has been decreasing by -14.48% on average per year.
EPS 1Y (TTM)-31.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.84%
Revenue 1Y (TTM)-20.34%
Revenue growth 3Y-29.03%
Revenue growth 5Y-14.48%
Sales Q2Q%36.11%

3.2 Future

The Earnings Per Share is expected to decrease by -2.10% on average over the next years.
The Revenue is expected to grow by 30.47% on average over the next years. This is a very strong growth
EPS Next Y-9.26%
EPS Next 2Y-13.04%
EPS Next 3Y-18.56%
EPS Next 5Y-2.1%
Revenue Next Year-31.56%
Revenue Next 2Y-2.11%
Revenue Next 3Y9.15%
Revenue Next 5Y30.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TNG.PA Yearly Revenue VS EstimatesTNG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
TNG.PA Yearly EPS VS EstimatesTNG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNG.PA Price Earnings VS Forward Price EarningsTNG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNG.PA Per share dataTNG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

A cheap valuation may be justified as TNG's earnings are expected to decrease with -18.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.04%
EPS Next 3Y-18.56%

More info and screens

0

5. Dividend

5.1 Amount

TNG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSGENE SA

EPA:TNG (11/28/2025, 5:26:44 PM)

1.02

-0.06 (-5.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04
Earnings (Next)03-25 2026-03-25/amc
Inst Owners0.68%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner ChangeN/A
Market Cap135.41M
Revenue(TTM)6.08M
Net Income(TTM)-33.97M
Analysts82.86
Price Target1.8 (76.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-521.43%
EPS NY rev (3m)-636.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.05
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.77%
ROA(5y)-43.73%
ROE(3y)-151.05%
ROE(5y)-103.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.08%
Cap/Sales 22.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -3.32
F-Score2
WACC7.7%
ROIC/WACCN/A
Cap/Depr(3y)165.93%
Cap/Depr(5y)113.96%
Cap/Sales(3y)33.44%
Cap/Sales(5y)22.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.84%
EPS Next Y-9.26%
EPS Next 2Y-13.04%
EPS Next 3Y-18.56%
EPS Next 5Y-2.1%
Revenue 1Y (TTM)-20.34%
Revenue growth 3Y-29.03%
Revenue growth 5Y-14.48%
Sales Q2Q%36.11%
Revenue Next Year-31.56%
Revenue Next 2Y-2.11%
Revenue Next 3Y9.15%
Revenue Next 5Y30.47%
EBIT growth 1Y-18.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.19%
EBIT Next 3Y-19.33%
EBIT Next 5YN/A
FCF growth 1Y30.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.37%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSGENE SA / TNG.PA FAQ

What is the ChartMill fundamental rating of TRANSGENE SA (TNG.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to TNG.PA.


What is the valuation status for TNG stock?

ChartMill assigns a valuation rating of 0 / 10 to TRANSGENE SA (TNG.PA). This can be considered as Overvalued.


Can you provide the profitability details for TRANSGENE SA?

TRANSGENE SA (TNG.PA) has a profitability rating of 0 / 10.


How financially healthy is TRANSGENE SA?

The financial health rating of TRANSGENE SA (TNG.PA) is 0 / 10.